Metagenomi Therapeutics, Inc. Comprehensive Income
Metagenomi Therapeutics, Inc. (MGX) reported Comprehensive Income of -$27.56 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-10.
Financial Statements › Income Statement › Unrealized Gains
us-gaap:ComprehensiveIncomeNetOfTax · last filed 2026-08-10
- Metagenomi Therapeutics, Inc. comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2026-06-30 was -$27.56M.
- Metagenomi Therapeutics, Inc. comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2026-03-31 was -$23.36M.
- Metagenomi Therapeutics, Inc. comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2025-12-31 was -$22.64M.
- Metagenomi Therapeutics, Inc. comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2025-09-30 was -$20.39M.
- Metagenomi Therapeutics, Inc. comprehensive income (loss), net of tax, attributable to parent for fiscal 2025 was -$88.32M.
- Metagenomi Therapeutics, Inc. comprehensive income (loss), net of tax, attributable to parent for fiscal 2024 was -$77.25M.
- Metagenomi Therapeutics, Inc. comprehensive income (loss), net of tax, attributable to parent for fiscal 2023 was -$68.08M.
| Period end | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 3 month | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 6 month | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 9 month | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$27.56M 10-Q · filed 2026-08-10 | -$50.92M 10-Q · filed 2026-08-10 | -$73.56M derived: sum of 3 quarters · filed 2026-08-10 | -$93.96M derived: sum of 4 quarters · filed 2026-08-10 |
| 2026-03-31 | -$23.36M 10-Q · filed 2026-05-11 | -$46.00M derived: sum of 2 quarters · filed 2026-05-11 | -$66.40M derived: sum of 3 quarters · filed 2026-05-11 | -$86.55M derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-12-31 | -$22.64M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | -$43.03M derived: sum of 2 quarters · filed 2026-03-05 | -$63.19M derived: sum of 3 quarters · filed 2026-08-10 | -$88.32M 10-K · filed 2026-03-05 |
| 2025-09-30 | -$20.39M 10-Q · filed 2025-11-12 | -$40.55M derived: sum of 2 quarters · filed 2026-08-10 | -$65.68M 10-Q · filed 2025-11-12 | -$90.01M derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-06-30 | -$20.16M 10-Q · filed 2026-08-10 | -$45.28M 10-Q · filed 2026-08-10 | -$69.61M derived: sum of 3 quarters · filed 2026-08-10 | -$86.48M derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-03-31 | -$25.13M 10-Q · filed 2026-05-11 | -$49.45M derived: sum of 2 quarters · filed 2026-05-11 | -$66.32M derived: sum of 3 quarters · filed 2026-05-11 | -$77.05M derived: sum of 4 quarters · filed 2026-05-11 |
| 2024-12-31 | -$24.33M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | -$41.20M derived: sum of 2 quarters · filed 2026-03-05 | -$51.92M derived: sum of 3 quarters · filed 2026-03-05 | -$77.25M 10-K · filed 2026-03-05 |
| 2024-09-30 | -$16.87M 10-Q · filed 2025-11-12 | -$27.59M derived: sum of 2 quarters · filed 2025-11-12 | -$52.92M 10-Q · filed 2025-11-12 | -$71.96M derived: sum of 4 quarters · filed 2025-11-12 |
| 2024-06-30 | -$10.73M 10-Q · filed 2025-08-12 | -$36.05M 10-Q · filed 2025-08-12 | -$55.09M derived: sum of 3 quarters · filed 2025-08-12 | -$74.84M derived: sum of 4 quarters · filed 2025-08-12 |
| 2024-03-31 | -$25.33M 10-Q · filed 2025-05-13 | -$44.36M derived: sum of 2 quarters · filed 2025-05-13 | -$64.11M derived: sum of 3 quarters · filed 2025-05-13 | -$77.30M derived: sum of 4 quarters · filed 2025-05-13 |
| 2023-12-31 | -$19.03M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-17 | -$38.78M derived: sum of 2 quarters · filed 2025-03-17 | -$51.97M derived: sum of 3 quarters · filed 2025-03-17 | -$68.08M 10-K · filed 2025-03-17 |
| 2023-09-30 | -$19.75M 10-Q · filed 2024-11-13 | -$32.93M derived: sum of 2 quarters · filed 2024-11-13 | -$49.05M 10-Q · filed 2024-11-13 | |
| 2023-06-30 | -$13.18M 10-Q · filed 2024-08-14 | -$29.30M 10-Q · filed 2024-08-14 | ||
| 2023-03-31 | -$16.11M 10-Q · filed 2024-05-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Scilex Holding Co (SCLX) | United States | $0.042B | -0.14 |
| LeonaBio, Inc. (LONA) | United States | $0.047B | -0.61 |
| Instil Bio, Inc. (TIL) | United States | $0.048B | -1.73 |
| Tevogen Inc. (TVGN) | United States | $0.049B | |
| aTYR PHARMA INC (ATYR) | United States | $0.033B | -0.98 |
| Inmune Bio, Inc. (INMB) | United States | $0.056B | -2.48 |
| ImageneBio, Inc. (IMA) | United States | $0.056B | -1.31 |
| Quince Therapeutics, Inc. (QNCX) | United States | $0.031B | |
| CEL SCI CORP (CVM) | United States | $0.030B | -0.81 |
| BioAtla, Inc. (BCAB) | United States | $0.058B | -0.21 |